How Xgeva Is Administered
Xgeva (denosumab) is given as a subcutaneous injection, typically every 4 weeks. Healthcare providers administer it in the upper arm, upper thigh, or abdomen, rotating sites to avoid irritation. Patients cannot self-administer it.[1]
Dosage for Different Conditions
For bone metastases from solid tumors or multiple myeloma, adults receive 120 mg every 4 weeks. Premedication with calcium and vitamin D is required daily to prevent hypocalcemia. No dose adjustments for mild renal impairment; monitor closely in severe cases.[1]
Who Gives the Injection
Only trained healthcare professionals administer Xgeva due to risks like osteonecrosis of the jaw. It's not approved for home use, unlike Prolia (same drug, 60 mg dose for osteoporosis).1
How Xgeva Differs from Prolia Administration
Both are subcutaneous denosumab injections, but Xgeva uses a higher 120 mg dose in a prefilled syringe for cancer-related bone issues, while Prolia's 60 mg can sometimes be self-injected by patients after training. Same sites and frequency apply.1
What If a Dose Is Missed
Administer as soon as possible, then resume the 4-week schedule. Do not double doses. Interrupt if severe hypocalcemia or renal issues occur.[1]
Common Administration Side Effects
Injection site reactions (redness, pain, swelling) affect about 8% of patients. Serious risks include hypocalcemia (correct with supplements), jaw bone problems, and atypical femur fractures—dental checks recommended before starting.[1]
[1]: https://www.xgevahcp.com/full-prescribing-information